NCT05496686 - Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 21, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

February 25, 2029

Conditions

Uveal MelanomaMetastatic

Interventions

DRUG

4.7 microCi 225Ac-MTI-201

4.7 microCi intravenous solution

DRUG

9.5 microCi of 225Ac-MTI-201

9.5 microCi intravenous solution

DRUG

19 microCi of 225Ac-MTI-201

19 microCi intravenous solution

DRUG

38 microCi of 225Ac-MTI-201

38 microCi intravenous solution

DRUG

76 microCi of 225Ac-MTI-201

76 microCi intravenous solution

DRUG

152 microCi of 225Ac-MTI-201

152 microCi intravenous solution

DRUG

254 microCi of 225Ac-MTI-201

254 microCi intravenous solution

DRUG

424 microCi of 225Ac-MTI-201

424 microCi intravenous solution

DRUG

564 microCi of 225Ac-MTI-201

564 microCi intravenous solution

DRUG

750 microCi of 225Ac-MTI-201

750 microCi intravenous solution

DRUG

998 microCi of 225Ac-MTI-201

998 microCi intravenous solution

DRUG

1327 microCi of 225Ac-MTI-201

1327 microCi intravenous solution

Trial Locations (1)

33612

RECRUITING

H. Lee Moffitt Cancer Center and Research Institute, Tampa